Condition: Limb Girdle Muscular Dystrophy · Limb-Girdle Muscular Dystrophy Type 2 · LGMD2I · Sponsor: AskBio Inc
The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
This description comes directly from the study's public registry record.
AskFirst Patient Engagement · 919-561-6210 · AskFirst@askbio.com
myTomorrows (see link below in reference section)
Always discuss trial participation with your own doctor first.
| University of California - Irvine | Irvine, California, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Kennedy Krieger Institute | Baltimore, Maryland, United States | Recruiting |
| VCU | Richmond, Virginia, United States | Recruiting |
| University of Washington Medical Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05230459